Tonhua Dongbao Receives Liraglutide Injection Registration Certificate in Nicaragua

GateNews
According to an announcement on May 25, Tonhua Dongbao received a drug registration certificate for liraglutide injection from Nicaragua's National Health Regulatory Authority (ANRS). Liraglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used to help diabetes patients control blood sugar by stimulating insulin secretion from the pancreas. The company has begun preparations for product manufacturing, though actual sales may be affected by market demand, regulatory changes, and competition.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments